ANHEART THERAPEUTICS
AnHeart Therapeutics is a developer of innovative pharmaceutical products. The company is focused on acquiring, developing and commercializing innovative pharmaceutical products that improve human health and quality of life. It's main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.
ANHEART THERAPEUTICS
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.anhearttherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+(86)(0571) 5626-3086
Email Addresses:
[email protected]
Total Funding:
75.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Apache Global Site Tag Euro
Similar Organizations
AmbAgon Therapeutics
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Dianthus Therapeutics
Dianthus Therapeutics is a biotech company developer of therapeutics and drugs.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Sage Partners
Sage Partners investment in Series B - AnHeart Therapeutics
Innovent Biologics
Innovent Biologics investment in Series B - AnHeart Therapeutics
Octagon Capital Advisors
Octagon Capital Advisors investment in Series B - AnHeart Therapeutics
Laurion Capital Management
Laurion Capital Management investment in Series B - AnHeart Therapeutics
Cenova
Cenova investment in Series B - AnHeart Therapeutics
Decheng Capital
Decheng Capital investment in Series A - AnHeart Therapeutics
Key Employee Changes
Official Site Inspections
http://www.anhearttherapeutics.com Semrush global rank: 2.65 M Semrush visits lastest month: 6.43 K
- Host name: ec2-34-192-255-123.compute-1.amazonaws.com
- IP address: 34.192.255.123
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "AnHeart Therapeutics"
AnHeart Therapeutics - Crunchbase Company Profile & Funding
Organization. AnHeart Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. AnHeart Therapeutics is a developer โฆSee details»
AnHeart Therapeutics | Taletrectinib | Safusidenib | AB-329
AnHeart Therapeutics is a clinical stage global biopharmaceutical company developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need.See details»
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Apr 10, 2024 Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Shareholders of Nuvation Bio and โฆSee details»
About ANHEART THERAPEUTICS | DxMultiomics
AnHeart is supported by leading life sciences investors and have built an organization with deep oncology drug discovery and development expertise, with offices in New York and Shanghai. โฆSee details»
Press Release - anhearttherapeutics.com
Nov 9, 2023 AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads. November 9, 2023. NEW YORK, NY, November 9, 2023 โ AnHeart โฆSee details»
AnHeart Therapeutics - LinkedIn
AnHeart Therapeutics Biotechnology Research New York, New York 4,128 followers AnHeart is now a Nuvation Bio company.See details»
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock โฆ
Mar 25, 2024 Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds โฆSee details»
AnHeart Therapeutics Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AnHeart Therapeutics Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
AnHeart Therapeutics - The Org
AnHeart Therapeutics (โAnHeartโ) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential โฆSee details»
AnHeart Therapeutics Appoints Charlotte Arnold as Chief โฆ
Sep 28, 2023 AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer. September 28, 2023. NEW YORK, NY, September 28, 2023 โ AnHeart Therapeutics โฆSee details»
AnHeart Therapeutics and Foundation Medicine Announce โฆ
Dec 14, 2023 NEW YORK, NY and CAMBRIDGE, Mass. โ AnHeart Therapeutics (โAnHeartโ), a global clinical-stage biopharmaceutical company developing novel precision therapies for โฆSee details»
AnHeart Therapeutics - PitchBook
AnHeart Therapeutics General Information Description. Operator of a biopharmaceutical company intended to improve the lives of cancer patients. The company develops a pipeline of novel โฆSee details»
AnHeart Therapeutics Expands U.S. Leadership With Development โฆ
Nov 9, 2023 We are supported by leading life sciences investors and have built an organization with deep oncology drug discovery and development expertise, with offices in New York and โฆSee details»
AnHeart Therapeutics - Overview, News & Similar companies
AnHeart Therapeutics contact info: Phone number: (212) 466-6378 Website: www.anhearttherapeutics.com What does AnHeart Therapeutics do? AnHeart Therapeutics is โฆSee details»
Press Release - anhearttherapeutics.com
Mar 21, 2022 For questions about the ongoing trials, please contact [email protected]. About AnHeart Therapeutics AnHeart Therapeutics โฆSee details»
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock
Mar 25, 2024 Management and Organization. Nuvation Bio will continue to be led by its current management team, including David Hung, M.D., its Founder, Chief Executive Officer, and โฆSee details»
AnHeart Therapeutics and Foundation Medicine Announce โฆ
Dec 14, 2023 NEW YORK & CAMBRIDGE, Mass., December 14, 2023--AnHeart Therapeutics and Foundation Medicine announce collaboration to develop tissue-based and liquid-based โฆSee details»
AnHeart Therapeutics Announces Formation of Scientific Advisory โฆ
Sep 22, 2021 AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need. For more information, please visit โฆSee details»
AnHeart Therapeutics | ้ข่ฑ - ้ข่ฑ (ไธญๅฝ)
Today AnHeart and Innovent Biologics announced that Chinaโs National Medical Products Administration (NMPA) accepted a New Drug Application (NDA) for our investigational โฆSee details»
Press Release - AnHeart Therapeutics
Jun 16, 2021 For questions about the ongoing trials, please contact [email protected]. About AnHeart Therapeutics AnHeart Therapeutics โฆSee details»